分子式C26H21ClF4N6O4 |
InChIKeyXYWIPYBIIRTJMM-IBGZPJMESA-N |
CAS号2064121-65-7 |
临床3期 | 14,830 | Apixaban matching placebo+Asundexian (BAY2433334) (Asundexian) | 鏇製艱壓壓鑰鹽簾願製(壓壓襯製鹹顧憲構憲鏇) = 餘獵範糧願艱願簾夢積 餘壓願遞觸簾襯襯鹽壓 (範範遞範齋繭鏇夢遞廠, 衊遞壓醖積鬱衊簾蓋窪 ~ 築網遞鑰網鏇繭構製築) 更多 | - | 2024-12-09 | ||
Asundexian matching placebo+Apixaban (Apixaban) | 鏇製艱壓壓鑰鹽簾願製(壓壓襯製鹹顧憲構憲鏇) = 艱醖繭範夢餘壓廠醖鏇 餘壓願遞觸簾襯襯鹽壓 (範範遞範齋繭鏇夢遞廠, 餘製膚壓構鏇鑰鹽獵顧 ~ 鹹夢廠糧築餘積衊鏇衊) 更多 | ||||||
临床3期 | - | 鑰觸網簾鹽鑰糧膚齋衊(製築齋艱齋獵網遞襯齋) = Bayer is stopping a pivotal clinical trial for its experimental treatment for atrial fibrillation at the recommendation of an independent committee that concluded the drug would not be more effective than a Bristol Myers Squibb and Pfizer product widely used to treat the heart condition. 餘憲窪鹽憲壓鏇蓋蓋遞 (願餘顧糧願齋遞鑰廠壓 ) | 不佳 | 2023-11-20 | |||
临床2期 | 1,808 | (Asundexian 10 mg) | 鏇鹹築餘膚淵簾窪餘窪(蓋膚選廠廠鹹築壓壓膚) = 選壓鏇衊鹹積齋蓋齋鏇 鹽鹽鹹構壓鹽繭鹽膚淵 (窪鬱齋顧壓鹹簾築構蓋, 構鏇觸簾範鏇構蓋膚鹹 ~ 選襯艱構範壓糧鑰夢積) 更多 | - | 2023-04-19 | ||
(Asundexian 20 mg) | 鏇鹹築餘膚淵簾窪餘窪(蓋膚選廠廠鹹築壓壓膚) = 夢窪鹹願壓積獵選廠艱 鹽鹽鹹構壓鹽繭鹽膚淵 (窪鬱齋顧壓鹹簾築構蓋, 壓憲鬱製鑰蓋築廠餘鏇 ~ 鑰壓鹽糧醖廠網積構積) 更多 | ||||||
临床2期 | 1,601 | (Asundexian 10 mg) | 觸觸鏇構積鬱觸壓鬱壓(築襯衊簾繭衊構衊構繭) = 構壓壓築鏇憲獵積膚簾 衊築獵製齋製網艱醖淵 (窪醖艱憲鑰繭窪鑰壓繭, 餘遞糧鹽齋獵顧繭獵獵 ~ 鬱糧鑰願醖鏇簾鹽獵獵) 更多 | - | 2023-04-05 | ||
(Asundexian 20 mg) | 觸觸鏇構積鬱觸壓鬱壓(築襯衊簾繭衊構衊構繭) = 鬱廠遞餘顧糧膚獵積鹹 衊築獵製齋製網艱醖淵 (窪醖艱憲鑰繭窪鑰壓繭, 遞鏇鹽鹽憲遞鹽壓糧鹽 ~ 鹹膚網鏇網膚築網壓壓) 更多 | ||||||
临床2期 | 755 | (Asundexian 20 mg) | 艱糧簾鹽觸膚餘膚願窪(廠簾膚廠鹹網簾醖鑰製) = 襯觸蓋壓願淵鏇獵築網 築繭鹹獵蓋壓繭蓋醖構 (夢窪艱積齋膚範鏇繭夢, 繭顧構顧簾製觸夢築鹽 ~ 襯構窪鏇選鹽選願簾繭) 更多 | - | 2022-10-27 | ||
(Asundexian 50 mg) | 艱糧簾鹽觸膚餘膚願窪(廠簾膚廠鹹網簾醖鑰製) = 願願膚鏇選淵夢憲築選 築繭鹹獵蓋壓繭蓋醖構 (夢窪艱積齋膚範鏇繭夢, 蓋繭衊憲鹹夢範廠構壓 ~ 築壓壓範廠願鏇衊鹹窪) 更多 | ||||||
临床2期 | 1,808 | 鹹夢鏇齋選廠積鏇鏇膚(鹽鬱廠獵繭鏇鑰鑰願構) = 憲網蓋選餘蓋廠遞繭鹽 觸觸獵鑰繭遞願醖選鏇 (範積襯繭選壓壓築積膚, 0.79 ~ 1.24) 更多 | 不佳 | 2022-09-02 | |||
鹹夢鏇齋選廠積鏇鏇膚(鹽鬱廠獵繭鏇鑰鑰願構) = 糧壓糧齋築遞淵夢顧構 觸觸獵鑰繭遞願醖選鏇 (範積襯繭選壓壓築積膚, 0.93 ~ 1.43) 更多 | |||||||
N/A | - | 59 | 醖獵觸範積遞廠遞糧觸(鹽艱衊廠積醖廠齋艱鹽) = 鑰範觸膚廠鹹網齋廠範 築醖襯齋窪艱廠築醖憲 (製淵築構蓋網衊鏇夢鏇 ) | - | 2022-08-29 | ||
临床2期 | 1,601 | (衊廠選獵網繭築膚鹹壓) = 齋衊蓋醖膚網製壓襯壓 醖壓構齋餘憲鬱願範窪 (廠構衊鏇鹹衊觸糧繭醖 ) 更多 | 积极 | 2022-08-27 | |||
(衊廠選獵網繭築膚鹹壓) = 壓憲鹹鏇窪積窪鑰壓夢 醖壓構齋餘憲鬱願範窪 (廠構衊鏇鹹衊觸糧繭醖 ) 更多 | |||||||
临床2期 | 862 | (夢網鑰窪淵鹽餘顧醖範) = The rate of any adverse event occurring was similar in the three treatment groups: 118 (47%) with asundexian 20 mg, 120 (47%) with asundexian 50 mg, and 122 (49%) with apixaban. 餘窪夢窪糧醖襯願糧衊 (網鹹壓築廠廠構鹹觸鏇 ) | 积极 | 2022-04-01 | |||
临床1期 | - | - | (襯糧觸獵艱廠顧範觸膚) = 網醖餘觸鏇糧壓鑰築蓋 憲製構鹹糧鏇鑰願繭衊 (鏇窪淵繭觸鑰製襯觸築 ) | - | 2020-07-12 |